Understanding HIV phenotypic resistance testing: Usefulness in managing treatment-experienced patients

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

This review discusses how "virtual" and conventional phenotypic assays establish clinical cutoffs predictive of response in HIV isolates from antiretroviral-experienced patients. Sophisticated phenotypic assays that incorporate linear regression modeling and conventional phenotypic assays have been used to define and validate clinical cutoffs (i.e. the correlation between viral susceptibility and treatment response) for most antiretrovirals, including the newer protease inhibitors. Using these clinical cutoff values, clinical data show that the newer protease inhibitors retain activity against the majority of isolates from treatment-experienced patients and from those with baseline resistance to multiple protease inhibitors. The utility of phenotypic resistance testing methods have therefore been validated in the clinical setting. In summary, HIV drug resistance testing is currently the recommended standard of care for the selection of antiretroviral regimens for HIV-infected patients in multiple clinical settings. An understanding of the basic principles of phenotypic resistance testing is crucial for providing optimal care, particularly for antiretroviral-experienced patients.

Original languageEnglish (US)
Pages (from-to)223-230
Number of pages8
JournalAIDS Reviews
Volume11
Issue number4
StatePublished - Oct 1 2009

Fingerprint

Protease Inhibitors
HIV
Therapeutics
Standard of Care
Drug Resistance
Linear Models

Keywords

  • Darunavir
  • Genotype
  • HIV
  • Phenotype
  • Resistance
  • Tipranavir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Understanding HIV phenotypic resistance testing : Usefulness in managing treatment-experienced patients. / MacArthur, Rodger David.

In: AIDS Reviews, Vol. 11, No. 4, 01.10.2009, p. 223-230.

Research output: Contribution to journalReview article

@article{263c332e0c1e486a98ecc84fb6e8b23d,
title = "Understanding HIV phenotypic resistance testing: Usefulness in managing treatment-experienced patients",
abstract = "This review discusses how {"}virtual{"} and conventional phenotypic assays establish clinical cutoffs predictive of response in HIV isolates from antiretroviral-experienced patients. Sophisticated phenotypic assays that incorporate linear regression modeling and conventional phenotypic assays have been used to define and validate clinical cutoffs (i.e. the correlation between viral susceptibility and treatment response) for most antiretrovirals, including the newer protease inhibitors. Using these clinical cutoff values, clinical data show that the newer protease inhibitors retain activity against the majority of isolates from treatment-experienced patients and from those with baseline resistance to multiple protease inhibitors. The utility of phenotypic resistance testing methods have therefore been validated in the clinical setting. In summary, HIV drug resistance testing is currently the recommended standard of care for the selection of antiretroviral regimens for HIV-infected patients in multiple clinical settings. An understanding of the basic principles of phenotypic resistance testing is crucial for providing optimal care, particularly for antiretroviral-experienced patients.",
keywords = "Darunavir, Genotype, HIV, Phenotype, Resistance, Tipranavir",
author = "MacArthur, {Rodger David}",
year = "2009",
month = "10",
day = "1",
language = "English (US)",
volume = "11",
pages = "223--230",
journal = "AIDS Reviews",
issn = "1139-6121",
publisher = "Publicaciones Permanyer",
number = "4",

}

TY - JOUR

T1 - Understanding HIV phenotypic resistance testing

T2 - Usefulness in managing treatment-experienced patients

AU - MacArthur, Rodger David

PY - 2009/10/1

Y1 - 2009/10/1

N2 - This review discusses how "virtual" and conventional phenotypic assays establish clinical cutoffs predictive of response in HIV isolates from antiretroviral-experienced patients. Sophisticated phenotypic assays that incorporate linear regression modeling and conventional phenotypic assays have been used to define and validate clinical cutoffs (i.e. the correlation between viral susceptibility and treatment response) for most antiretrovirals, including the newer protease inhibitors. Using these clinical cutoff values, clinical data show that the newer protease inhibitors retain activity against the majority of isolates from treatment-experienced patients and from those with baseline resistance to multiple protease inhibitors. The utility of phenotypic resistance testing methods have therefore been validated in the clinical setting. In summary, HIV drug resistance testing is currently the recommended standard of care for the selection of antiretroviral regimens for HIV-infected patients in multiple clinical settings. An understanding of the basic principles of phenotypic resistance testing is crucial for providing optimal care, particularly for antiretroviral-experienced patients.

AB - This review discusses how "virtual" and conventional phenotypic assays establish clinical cutoffs predictive of response in HIV isolates from antiretroviral-experienced patients. Sophisticated phenotypic assays that incorporate linear regression modeling and conventional phenotypic assays have been used to define and validate clinical cutoffs (i.e. the correlation between viral susceptibility and treatment response) for most antiretrovirals, including the newer protease inhibitors. Using these clinical cutoff values, clinical data show that the newer protease inhibitors retain activity against the majority of isolates from treatment-experienced patients and from those with baseline resistance to multiple protease inhibitors. The utility of phenotypic resistance testing methods have therefore been validated in the clinical setting. In summary, HIV drug resistance testing is currently the recommended standard of care for the selection of antiretroviral regimens for HIV-infected patients in multiple clinical settings. An understanding of the basic principles of phenotypic resistance testing is crucial for providing optimal care, particularly for antiretroviral-experienced patients.

KW - Darunavir

KW - Genotype

KW - HIV

KW - Phenotype

KW - Resistance

KW - Tipranavir

UR - http://www.scopus.com/inward/record.url?scp=74249117632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249117632&partnerID=8YFLogxK

M3 - Review article

C2 - 19940949

AN - SCOPUS:74249117632

VL - 11

SP - 223

EP - 230

JO - AIDS Reviews

JF - AIDS Reviews

SN - 1139-6121

IS - 4

ER -